- Home
- FISI vs ANL Comparison
FISI vs ANL Comparison
Compare FISI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FISI | ANL |
|---|---|---|
| Founded | 1817 | 2004 |
| Country | United States | Cayman Islands |
| Employees | 631 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.4M | 703.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FISI | ANL |
|---|---|---|
| Price | $34.94 | $12.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.00 | $20.00 |
| AVG Volume (30 Days) | 93.1K | ★ 637.3K |
| Earning Date | 04-23-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.41 | $0.88 |
| 52 Week High | $35.67 | $17.25 |
Technical Indicators
Market Signals| Indicator | FISI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 50.99 |
| Support Level | $26.91 | $6.92 |
| Resistance Level | $35.49 | $17.25 |
| Average True Range (ATR) | 0.80 | 2.51 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 67.50 | 51.54 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.